Pharmacogenomics of Multiple Sclerosis: Sieving treatment biomarkers from blood gene-expression profiles (PP-30)

Abstract

Introduction: Over the past two decades, various novel disease-modifying drugs for multiple sclerosis (MS) have been approved. However, there is high variability in the patient response to the available medications, which is hypothesized to be partly attributed to genetics. our aim was To conduct a systematic review of the current literature on the pharmacogenomics of MS therapy to find candidate genes to respond to treatment. Methods: A systematic literature search was conducted using the GEO database and PubMed searching for articles investigating the role of genetic variation in response to disease-modifying MS treatments include: interferon beta, and glatiramer acetate . Results: In recent years, hypothesis-free approaches identified novel candidate genes that remain to be validated. We identified many candidate genes that were effective in responding to treatment for MS patients such as : CCR5, STAT1, IFIT3, OASL, HLA-DRB1, IL10, & etc. Discussion: At the moment, there is no available clinically actionable pharmacogenomic biomarker that would enable more personalized treatment of MS. So, finding the biomarkers that can predict the probability of responsiveness in patients at the early stages of disease diagnosis is very important and it can minimize the chance of injury from the disease. Of course more large-scale studies with a uniform design are needed to identify novel and validate existing pharmacogenomics findings.

Keywords

• pharmacogenomics
• multiple sclerosis